Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Axitinib Disappoints As RCC Adjuvant Therapy

Executive Summary

An interim analysis has recommended stopping the Phase III ATLAS study because axitinib was failing to show it extended disease-free survival when used as adjuvant therapy in earlier-stage renal cell carcinoma patients. However, combination studies of axitinib with immuno-oncology agents will continue.

Advertisement

Related Content

Merck KGaA/SFJ's Abituzumab Evaluated For Left-Sided Metastatic Colon Cancer
Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC122880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel